Literature DB >> 28781466

Perioperative management of patient on aspirin: Current view.

Teena Bansal1.   

Abstract

Entities:  

Year:  2017        PMID: 28781466      PMCID: PMC5520613          DOI: 10.4103/joacp.JOACP_186_16

Source DB:  PubMed          Journal:  J Anaesthesiol Clin Pharmacol        ISSN: 0970-9185


× No keyword cloud information.
Sir, We read with interest the article published in J Anaesthesiol Clin Pharmacol 2016;32:103-5. Bhargava et al. reported a case of an elderly man with double vessel disease, poor left ventricular function, and concomitant anomalous origin of the left anterior descending artery from the right coronary artery for repair of irreducible obstructed paraumbilical hernia.[1] However, it raises certain issues. The authors had stopped aspirin preoperatively for their patient. When aspirin is held preoperatively, the aspirin withdrawal syndrome may significantly increase the risk of a major thromboembolic complication. This causes concerns particularly in the present scenario, where the patient in reference had poor left ventricular function (left ventricular ejection fraction 25%). For many operative procedures, the risk of perioperative bleeding while continuing aspirin is minimal as compared with the concomitant thromboembolic risks associated with aspirin withdrawal. We recommend that aspirin be continued perioperatively, however exceptions include intracranial, middle ear, posterior eye, intramedullary spine, and possibly transurethral prostatectomy surgery.[23] Aspirin is the most commonly used antiplatelet agent in the primary and secondary prevention of cardiovascular events. Aspirin withdrawal is associated with a “rebound” phenomenon that is prothrombotic and/or proinflammatory that plays a causative role in adverse events. This rebound hypothesis, as a scientific entity, can be defined as an increase in platelet reactivity following aspirin withdrawal, to a level exceeding that at baseline before initiation of aspirin therapy.[4] This rebound period is characterized by increased thromboxane production, decreased fibrinolysis, and a resultant clinical prothrombotic state. Platelet function rebound is dose dependent, with a more rapid rebound associated with withdrawal of lower aspirin doses.[3] In patients on antiplatelet therapy undergoing surgery, bridging antiplatelet therapy is started if warranted in the given situation instead of anticoagulants.[5] Discontinuation of aspirin preoperatively significantly compounds patient's thromboembolic risk because of rebound hypercoagulability. For an at-risk patient, the hypercoagulable state aggravated by the surgical procedure and further compounded by the aspirin withdrawal creates an ideal scenario for a major cardiac or vascular thromboembolic complication. Based on the current evidence, anesthesiologists should continue the perioperative use of aspirin for the beneficial effects on cardiovascular outcomes.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  5 in total

Review 1.  Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.

Authors:  Neal Stuart Gerstein; Peter Mark Schulman; Wendy Hawks Gerstein; Timothy Randal Petersen; Isaac Tawil
Journal:  Ann Surg       Date:  2012-05       Impact factor: 12.969

2.  The rebound phenomenon after aspirin cessation: the biochemical evidence.

Authors:  Richard F Alcock; Caroline J Reddel; Gabrielle J Pennings; Graham S Hillis; Jennifer L Curnow; David B Brieger
Journal:  Int J Cardiol       Date:  2014-04-08       Impact factor: 4.164

Review 3.  Perioperative management of antiplatelet therapy.

Authors:  A D Oprea; W M Popescu
Journal:  Br J Anaesth       Date:  2013-12       Impact factor: 9.166

Review 4.  Perioperative management of patients on chronic antithrombotic therapy.

Authors:  Thomas L Ortel
Journal:  Blood       Date:  2012-08-01       Impact factor: 22.113

5.  Perioperative management of a patient with left ventricular dysfunction and anomalous coronary arteries.

Authors:  Jyotsna Bhargava; Rajeev Lochan Tiwari; Mona Bana; Akhil Agarwal
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2016 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.